Thu, Apr 17, 2014, 2:52 PM EDT - U.S. Markets close in 1 hr 8 mins

Recent

% | $
Quotes you view appear here for quick access.

International Rectifier Corporation Message Board

johnnycat9 4 posts  |  Last Activity: Apr 10, 2014 12:37 PM Member since: Jun 28, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Where have you been? And what are the prospects for it being a threat to Afrezza? Looks like you are a bit late to the "Dance" with your latest attempt to bash MNKD. Time for you and your buddies to COVER....

  • Shorties need to give up on that one. Just read p. 103 of the briefing document. What will their next ploy be? How about claiming women will not use Afrezza because the inhaler will ruin their lipstick?

  • Reply to

    30-day wait or wash sale

    by samned2000 Apr 3, 2014 8:44 PM
    johnnycat9 johnnycat9 Apr 3, 2014 9:22 PM Flag

    The other replies have it right as far as I understand it. Up until now, it had been a few years since I'd done it. The only thing I would add to clarify things, as I understand them, is to say you get to use your loss ONLY when you SELL your newly bought (within 30 days) shares, something you may never do since you could die still owning them. If you sold at a loss of $2 last week, and bought back today at $7, your cost basis is now $9. If you sell at $12, your gain is $3, NOT $5. By the way, yes, I did it. I was buying back on Wednesday less than 30 days after I sold.

  • Once diabetics see the ads for Afrezza, they will beat the door down at their doctor's office to get a prescription and get off the needle. Last night in the news item on NBR they showed patients injecting themselves in the thigh and abdomen with the needle. Then they showed someone using the Afrezza inhaler, as small as a kid's toy whistle.... It would be an easy choice for me.

IRF
26.32+0.14(+0.53%)2:52 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.